UNIQUE / HUMAN CAPITAL

Y-mAbs Therapeutics A/S

Scientist / Principal Scientist Radiochemistry, CMC Development

Index

1. Company

EU
Y-mAbs Therapeutics A/S
Agern Allé 11
2970 Hørsholm
Denmark

Telephone: +45 70 26 14 14
E-mail: info@ymabs.com

US
Y-mAbs Therapeutics, Inc
230 Park Avenue, Suite 3350
New York, NY 10169
USA

Telephone: +1 646 885 8505
E-mail: info@ymabs.com

2. Profile

Y-mAbs Therapeutics is a commercial late-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company has a broad and advanced product pipeline.

Y-mAbs has one FDA approved product, DANYELZA® (naxitamab-gqgk), which targets tumors that express GD2, and one pivotal-stage product candidate, omburtamab, which targets tumors that express B7-H3.

Y-mAbs Therapeutics, Inc is a US publicly traded company (NASDAQ, YMAB). The technology is based on licenses from Memorial Sloan Kettering Cancer Center under an exclusive worldwide license and research collaboration agreement. They apply its world-class antibody capabilities to create life-changing immunotherapies for cancer patients of all ages.

Y-mAbs has several antibody platform technologies including naked IgG mAbs, IgG-based radioimmunotherapy (RIT), bivalent, T-cell engaging mAbs (Biclone), and new SADA platform for pre-targeting radio-immuno therapy (pRIT).

The product development team includes some of the most talented and experienced professionals in the antibody industry.

Discovery
Y-mAbs' laboratories are located in Nutley, NJ at the former site of the Roche Institute of Molecular Biology, a state-of-the art facility for the development of novel antibody-based therapeutic and diagnostic agents for pediatric and adult cancers of high unmet medical need. At Nutley site, antibody discovery protein engineering for optimal affinity, function, stability, manufacturability, and reduced risk of immunogenicity is performed.

CMC Development
The CMC development is handled at Y-mAbs' own office in Hørsholm, where SMEs and PMs secure and prepare the clinics and commercial supplies of all the products worldwide in collaboration with CMOs in both Europe and the US. Y-mAbs also have access to radiochemistry laboratories for further CMC development and activities.

Clinical & Regulatory

The clinical and regulatory groups at Y-mAbs oversee clinical aspects of all stages of product development, from early-stage clinical trials through license application, submission, product approval, and beyond. Y-mAbs is leading the clinical development of their investigational product candidates targeting the anti-ganglioside or disialoganglioside, GD2 antibody (regulatory and line extensions) and the B7-H3 originating from and created by MSKCC.

SADA technology:

Y-mAbs has partnered up with Memorial Sloan-Kettering Cancer Center and Massachisetts Institute of Technology in a worldwide exclusive license and research collaboration agreement to develop and commercialize antibody constructs based on the SADA-BiDE, Pre-targeted Radioimmuntherapy Platform (the "SADA technology"), a concept also referred to as Liquid Radiation™. The technology utilizes a targeted payload delivery methos where antibody constructs assemble in tetramers to radiate and bind to the tumor target.

Pipeline:

Preclinical and Research Pipeline

Product Candidate	Target	Anticipated Treatment	Next Anticipated Milestone
GD2-SADA	GD2	GD2 Positive solid tumors	IND 2021
GPA33-SADA	GPA33	Colon Therapeutic/Diagnostic	IND 2022
HER2-SADA	HER2	Breast Cancer	IND 2022
B7-H3-SADA	B7-H3	Prostate Cancer	IND 2022
huCD33-BsAb	CD33xCD3	Hematological Cancers Expressing CD33	IND 2021

Read more about Y-mAbs' pipeline here: https://ymabs.com/research-development/pipeline/.

3. History

Y-mAbs was founded in April 2014 by Thomas Gad, inspired by his daughter going through 6 years of treatment overcoming high-risk neuroblastoma, receiving break-through cancer immunotherapy at Memorial Sloan Kettering Cancer Center (MSK). He secured executive management and seed capital for inception of the company. Thomas is today Chairman of the Board of Directors, President, and Head of Business Development and Strategy.

4. Economy

Y-mAbs is in a strong financial position with blue chip investors and has completed a series of successful financial rounds, with $489 million raised to date.

5. Organisation

Y-mAbs has a management team with a proven track record and antibody drug development experience as well as expertise in running leading public biopharmaceutical companies.

Board of Directors:

Thomas Gad (Chairman) is Founder, President, and Head of Business Development and Strategy. Inspired by his daughter's transformational and challenging journey through years of high-risk neuroblastoma treatment and her experience receiving breakthrough immunotherapy at Memorial Sloan Kettering Cancer Center (MSKCC) to overcome the cancer, Mr. Gad founded Y-mAbs Therapeutics, securing executive management and seed capital for the inception of the Company. Mr. Gad has more than 12 years of experience in the pharmaceutical industry, including business development, senior management, financing, and licensing negotiations. Mr. Gad has a Bachelor of Science degree in Business Administration from Pepperdine University, California, US.

Claus Møller, MD, PhD, serves as Chief Executive Officer of the Company. Dr. Moller is the Founder of Azanta A/S and was the Chief Executive Officer of Azanta from 2009 to 2015. In addition, Dr. Moller has extensive experience in the pharmaceutical and biotechnology industries and was a co-founder of one of the largest European biotech companies, Genmab A/S, in 1999, where he served as Executive Vice President and Chief Operating Officer until 2008. Previous positions include Executive Vice President and Chief Medical and Operating Officer of OXiGENE, Inc., and Medical Director of Synthélabo Scandinavia. Dr. Moller received his MD and PhD degrees from the University of Copenhagen, Denmark.

Johan Wedell-Wedellsborg is Owner and Chairman of the Board of Weco Group, which he took over in 2001. Weco Group is primarily a Ship Owning Company, which operates within the

product tanker segment, multi-purpose vessels, RORO line and handy size bulk carriers. The shipping part of Weco Group records annual revenue of approximately $200 million. Besides shipping, Weco Group also is involved in realty investments, financial services, art and biotech. Wedell-Wedellsborg is educated within shipping in Hamburg, Germany and has also worked out of London in the United Kingdom and Houston, Texas.

Gérard Ber has more than 30 years of experience in Molecular Nuclear Medicine (MNM). In 2002, Dr. Ber co-founded Advanced Accelerator Applications S.A., and was its Chief Operating Officer from 2002 to 2018, when it was sold to Novartis AG. Dr. Ber grew Advanced Accelerator Applications from a start-up to a global leader in MNM and was a member of its Board of Directors from 2002 to 2015, when Advanced Accelerator Applications listed on the Nasdaq Global Select Market. He received his PhD degree in Pharmacy from the Scientific and Medical University of Grenoble.

Ashutosh Tyagi, M.D. has been a member of our Board of Directors since November 2017, representing until the end of 2018 Scopia Capital Management LP, or Scopia Capital, an institutional alternative asset management firm. Dr. Tyagi was with Scopia Capital from 2010 to 2018 (as a partner from 2012 to 2018). At Scopia Capital, Dr. Tyagi managed global health care investments and was a Co-Portfolio Manager of Scopia Capital's health care funds. Prior to joining Scopia, he worked at Lombard Odier, Morgan Stanley, and Citigroup. Dr. Tyagi received a B.A. in Asian Studies from the University of Michigan, an MBA from the University of Michigan Business School, and an M.D. from the University of Michigan School of Medicine.

James I. Healy, MD, PhD, has been a General Partner at Sofinnova Ventures, Inc., since 2000. Prior to this role, Dr. Healy held various positions at Bayer HealthCare Pharmaceuticals, Inc., Sanderling Ventures, and ISTA Pharmaceuticals, Inc. Dr. Healy is currently on the board of directors for Ascendis (ASND), Bolt (BOLT), Coherus (CHRS), Karuna (KRTX), Natera (NTRA), Nucana (NCNA), Y-mAbs (YMAB), and a board observer at Visen. Previously, Dr. Healy served as a board member for Amarin Corporation plc, Anthera Pharmaceuticals, Inc., Auris Medical Holding AG, Edge Therapeutics, Inc., Durata Therapeutics, Inc., Hyperion Therapeutics, Inc., InterMune, Inc., Interim Therapeutics plc, KaloBios Pharmaceuticals, Inc., CoTherix, Inc. and Movetis NV, in addition to a number of private companies. Dr. Healy holds a BA in Molecular Biology and a BA in Scandinavian Studies from the University of California, Berkeley, and an MD and a PhD in Immunology from Stanford University School of Medicine, California.

David N. Gill has over 30 years' experience in senior operating and financial roles in the life sciences industry. Mr. Gill currently serves as Chief Financial Officer of Perspectum Ltd., a UK based diagnostic tools company. He was previously the President and Chief Financial Officer of EndoChoice Holdings, Inc., a publicly traded medical device company focused on gastroenterology products that was acquired in November 2016. Prior to EndoChoice he was the Chief Financial Officer of INC Research from 2011 to 2013 after having served as an independent board member from 2007 through 2010. INC Research (now known as Syneos) is a large, global clinical research organisation (CRO) which provides outsourced pharmaceutical development services on a global basis. Earlier in his career, Mr. Gill served in a variety of senior executive leadership roles for several medical device companies, including TransEnterix,

NxStage Medical, CTI Molecular Imaging, Inc., Novoste Corporation and Dornier Medical Systems. He currently also serves as a director of the following public companies: Evolus, Inc. and Strongbridge Biopharma plc.

Laura J. Hamill has extensive experience in the biopharmaceutical industry, with over 30 years of global commercial experience in a variety of executive leadership positions. Most recently Ms. Hamill served as Executive Vice President, Worldwide Commercial Operations, for Gilead Sciences, Inc., where she was accountable for 2,200 employees and $22 billion in annual revenue and led the global commercial strategic direction and long-term planning. As a member of the executive team, she contributed to the corporate strategy and overall governance of the organisation. Over an 18-year career at Amgen, Ms. Hamill held a number of executive roles in the US and internationally. Her last role as Senior Vice President and General Manager included management of 2,000 employees across all Amgen's therapeutic areas with annual revenue of $20 billion. Ms. Hamill's areas of therapeutic expertise include inflammation, oncology, gene therapy, nephrology, osteoporosis, cardiovascular disease, migraine, HIV, hepatology, GI and anti-infectives. Since September 2019, Ms. Hamill has served on the board of directors of AnaptysBio, Inc., a publicly traded clinical-stage antibody-based biotechnology company. Since September 2020 Ms. Hamill has served on the board of directors of Acceleron Pharma, Inc., a publicly traded clinical stage biopharmaceutical company. Ms. Hamill holds a B.A. in business administration from the University of Arizona.

The Leadership Team:

- Chairman, Founder, President, & Head of Business Development & Strategy, Thomas Gad
- Chief Executive Officer, Claus Møller
- Chief Financial Officer, Treasurer, and Secretary, Bo Kruse
- SVP, Chief Technical Officer, Torben Lund-Hansen
- SVP, Chief Medical Officer, Vignesh Rajah
- SVP, Chief Operating Officer, Joris Wilms
- SVP, Chief Scientific Officer, Global Head Translational Medicine, Steen Lisby
- SVP, Chief Commercial Officer, Philip Herman

CMC Development Team:



6. Mission, culture, and values

Y-mAbs' mission is to become the world leader in developing better and safer antibody-based pediatric oncology products addressing clear unmet medical needs. They also seek to advance and expand its product pipeline into certain adult cancer indications and to leverage its extensive drug development capabilities and platform technology towards the creation of new types of bispecific antibodies.

Y-mAbs' commitment to bringing new therapeutics to the market to save and improve patients' lives is a strong motivation for employees at Y-mAbs. Y-mAbs' aim is to foster a culture of excellence and execution where employees are focused on clear priorities and are passionate about advancing tasks and programs. They work cross-functionally and internationally as one team to gain the most from all competencies.
Y-mAbs' employees work with determination and with respect for each other to achieve their tasks and common goals. They give individuals and teams the autonomy to drive development of innovative products and solutions, knowing that integrity is a core value throughout the company.

7. Job description

Position	Scientist / Principal Scientist Radiochemistry.
Reporting to	Senior Director, CMC Development, Tore Søderblom.
Place of work	Y-mAbs' Head Office in Hørsholm, Denmark.
Responsibilities	The Scientist / Principal Scientist Radiochemistry will be part of Y-mAbs' growth within the CMC Development team and become an integrated part of Y-mAbs' development activities within radiochemistry for their radiolabelled products candidates. The development activities will be directly linked to Y-mAbs' CMC projects as well as their general development activities, which partly will be conducted in nearby radioisotope laboratories. Key responsibilities: • Radiolabeling of early-stage lead candidates for Y-mAbs development programs • Radiolabeling of clinical and potential commercial products for Y-mAbs development programs • Prepare and maintain overall and detailed project plans and coordinate with internal and external stakeholders • Give input to the CMC part of regulatory documentation • Interaction with regulatory agencies • Secure clinical trial material • Initiation of change controls • Input in Product Quality Review/Annual Product Review • Review of deviations and quality investigations from CMOs, CTLs, and transporters • Participation in product recall activities You will act as a valuable contact in coordinating various activities in collaboration with Y-mAbs' CMO partners, which consist of both private companies and academia laboratories.
Success criteria	To succeed in this position, it is essential that the candidate has the right mindset, and possess in-depth knowledge within the field of matters such as Radiochemistry, Chemistry, and Nuclear Chemistry, and specifically can act as a subject matter expert on radiopharmaceutical products and biomolecules. Further, it is necessary that the candidate is highly motivated by these instances since it requires deep immersion and interest to gain new knowledge and know-how. Furthermore, the candidate will achieve success by being able to navigate, communicate and translate activities, initiatives and research across various functions, stakeholders, and departments. The interdisciplinary balance is essential for all parties, to unite their work and be able to achieve and create new, valuable results

	and keep developing towards the position as world leader in developing better and safer antibody-based pediatric oncology products addressing clear unmet medical needs.
Challenges	The field of Radiochemistry faces different challenges, which influences the daily work for the practises within. The field is very specialized and interdisciplinary and brings both complex and logistics challenges, which calls for various competencies and experiences. The Radiochemistry industry is heavily regulated, e.g., by GMP, while an ongoing need for further research and initiatives are blooming in the industry. This requires for the candidate, to be up to date on regulations, new discoveries, market demands e.g. The Scientist / Principal Scientist Radiochemistry will be working with various stakeholders both internally and externally, and it can be challenging to navigate between the different functions and departments and thereto be able to transfer, as to translate, the discoveries across the organisation, and make sure that the collaboration keeps running smoothly.
Development potential	Y-mAbs offers unique and exciting career opportunities in a growing and modern, international company, and operates with a flat management structure. There is room for individual development and immersion, as well as professional and personal growth opportunities, and they give individuals the autonomy to drive development of products and solutions. Y-mAbs is committed to establish good work life balance and personal time for their employees, by providing different benefits and maintaining an open and trusting atmosphere. As they are growing rapidly and expands their portfolio of collaboration, the candidate will achieve worldwide knowledge and experience within the pharmaceutical industry.
Travelling	Approximately 10-20 days pr. year, domestic as well as foreign trips.
Availability	As soon as possible.

8. Candidate profile

Language

You are proficient in English at a professional level, both written and spoken, since this is the corperate langauge.

Education

Preferably from the industry of Chemistry, with a postdoc background.

Domicile

Driving distance to the office in Hørsholm, Denmark.

Qualifications

Great expertise and knowledge in Chemistry/Radiochemistry/ Nuclear Chemistry, and a solid understanding of emerging research within the above. A minimum of 2 years' experience in the pharmaceutical industry and related products, or as a postdoc with experience from collaborating with relevant, pharmaceutical companies.

Furthermore, it is necessary that you possess knowledge on regulatory requirements for CMC documentations and GMP regulations, to give inputs to CMC part and be able to participate in relevant and current discussions on radiochemical issues. In addition, the candidate has experience with Quality Control of radiopharmaceutical products by different state of the art methods (HPLC, iTLC, Gamma spectrometry).

You have experience with synthesis, purification and analysis of biomolecules and molecules with different radioisotopes, preferably:

- Iodine (I-131)
- Lutetium (Lu-177)
- Actinium (Ac-225)
- Zirconium (Zr-89)
- And others to be decided

The candidate's professional qualifications rated on a scale from 1-5, where 1 = knowledge of and 5 = very experienced/expert level.

Qualifications	Level	Experience
In-depth knowledge in Radiochemistry	5	5-7 years
Synthesis, purification, and analysis of radiolabeled biomolecules	5	5-7 years
QC experience	3	2-3 years
Research and manufacturing	3	2-3 years
GXP Experience	3	2-3 years

Personal skills	You are an initiative, proactive, and ambitious person with a can-do attitude and great integrity. You are highly motivated and manage to familiarize yourself thoroughly in the market and products. You can work independently with multiple tasks and stakeholders, as well as being a great collaborator when the tasks require it. You have great analytical skills, an eye for the detail and good time management and planning skills. Last but not least, you are passioned for working in a company, that on a daily basis achieves to establish a better life for many people.

9. Contact persons at Unique Human Capital

CEO, Jørn Duhn	+45 21 75 19 25	E-mail jd@uhc.dk
Research Consultant, Emma Josephine Dahl	+45 51 43 43 17	E-mail ejd@uhc.dk
Business Coordinator, Malene Grastvedt	+45 51 44 60 33	E-mail mag@uhc.dk